NEW YORK (GenomeWeb) – Transgenomic today announced its shareholders have approved the previously announced planed merger with Precipio Diagnostics.

More than 90 percent of votes cast by Transgenomic's shareholders gave the go-ahead to the deal at a special shareholders meeting held on Monday, the firm said. Additionally, more than 95 percent of Precipio's voting members approved the merger.